Lipoprotein Glomerulopathy (LPG): A Comprehensive Disease Characteristics Report

Target Disease: Lipoprotein Glomerulopathy MONDO ID: MONDO:0012725 · OMIM: 611771 · Gene: APOE (HGNC:613; chr19q13.32) · Category: Mendelian (autosomal dominant, incomplete penetrance)

Summary

Lipoprotein glomerulopathy (LPG) is an ultra-rare, autosomal-dominant renal lipidosis caused by heterozygous (rarely homozygous) missense and small in-frame variants in the APOE gene, clustered in or near the LDL-receptor-binding region of apolipoprotein E (apoE). It is histologically defined by markedly dilated glomerular capillary loops occluded by lamellated, vacuolated, apoE-rich lipoprotein thrombi that lack foam cells and are negative for immunoglobulins and complement. Clinically, patients present with proteinuria/nephrotic syndrome, microscopic hematuria, and a type III hyperlipoproteinemia-like dyslipidemia with markedly elevated serum apoE. More than 200 cases have been reported worldwide since the entity was first described ~30 years ago, with cases concentrated in East Asia (Japan, China) through documented founder variants (PMID: 40306438; PMID: 35602473).

The core mechanism is conformational: LPG-associated APOE variants (predominantly proline substitutions and small deletions/duplications around residues 136–158) thermodynamically destabilize the N-terminal domain of apoE, driving it toward a molten-globule-like state with increased exposed hydrophobic surface and aggregation propensity. The misfolded, aggregation-prone apoE forms aberrant lipoprotein particles that deposit as intraglomerular thrombi, occluding dilated capillaries and producing proteinuria and progressive chronic kidney disease (PMID: 23110818; PMID: 31874799). The etiologic role of mutant apoE has been confirmed in vivo: adenoviral transduction of apoE-Sendai (and apoE-Kyoto) into apoE-deficient mice reproduces LPG-like glomerular lesions (PMID: 16431249; PMID: 19459027; PMID: 33663537).

LPG carries a guarded prognosis — approximately half of patients progress to end-stage kidney disease (ESKD) within 1–27 years — but it is not steroid-responsive. The cornerstone of treatment is lipid-lowering therapy, especially fibrates (fenofibrate, bezafibrate, and the selective PPARα modulator pemafibrate), often combined with RAAS blockade (ACEi/ARB); these can markedly reduce proteinuria and, in some reports, induce complete remission. Because the pathogenic apoE is a circulating protein, LPG recurs after kidney transplantation. Diagnosis rests on two pillars: a characteristic kidney biopsy plus molecular confirmation by APOE sequencing (PMID: 40306438; PMID: 38769490).

1. Disease Information

Overview. LPG is an inherited glomerular disease in which apoE-rich lipoproteins accumulate as "thrombi" within dilated glomerular capillary lumina, producing proteinuria, nephrotic syndrome, and progressive renal dysfunction. It is a renal lipidosis distinct from systemic lipid storage diseases and from immune-complex glomerulonephritis. Definitive diagnosis requires molecular genetic analysis of APOE in addition to characteristic biopsy findings (PMID: 40306438).

"Lipoprotein glomerulopathy (LPG) is an ultrarare kidney disorder caused by pathogenic variants in the APOE gene. Although kidney biopsy presents typical findings, such as dilated capillary loops containing lipoprotein thrombi, definitive diagnosis requires molecular genetic analysis of APOE." — PMID: 40306438

Key identifiers.

Resource Identifier
MONDO MONDO:0012725
OMIM 611771 (Lipoprotein glomerulopathy)
Gene APOE (HGNC:613), chromosome 19q13.32
MeSH Closest indexing via "Apolipoproteins E" / glomerular disease terms
ICD-10 No specific LPG code; coded under glomerular disease categories (e.g., N05.-)

Synonyms / alternative names. Lipoprotein glomerulopathy; LPG; apoE-associated lipoprotein glomerulopathy. Named variant subtypes commonly appear in the literature (e.g., apoE-Sendai, apoE-Kyoto, apoE-Osaka/Kurashiki, apoE-Chicago, apoE-Tokyo/Maebashi, apoE-Guangzhou, apoE-Kanto), referring to specific causal mutations rather than distinct diseases.

Information source. The evidence base is derived from aggregated disease-level resources — case reports, small clinical series, meta-analyses, and in vitro/animal mechanistic studies — rather than large EHR/population cohorts, reflecting the disease's rarity (PMID: 35602473).

2. Etiology

Disease causal factors. LPG is a purely monogenic genetic disorder caused by variants in APOE. No infectious or toxic cause is implicated, and no environmental trigger is required. ApoE is the principal ligand for LDL-receptor–mediated clearance of triglyceride-rich/remnant lipoproteins; LPG-causing variants lie in or near the receptor-binding region (residues ~136–158), producing a dysbetalipoproteinemia-like (type III) plasma profile with remnant accumulation and elevated serum apoE (PMID: 27277824; PMID: 23407349).

"Apolipoprotein (apo) E was initially described as a lipid transport protein and major ligand for low density lipoprotein (LDL) receptors with a role in cholesterol metabolism and cardiovascular disease." — PMID: 27277824

Genetic risk factors. The causal variants are heterozygous APOE missense substitutions (frequently arginine→proline) and small in-frame deletions/duplications near the LDL-receptor-binding site. Recurrent variants include apoE-Sendai (Arg145Pro), apoE-Kyoto (Arg25Cys; signal-inclusive Arg43Cys), apoE-Osaka/Kurashiki (Arg158Pro), apoE-Chicago (Arg147Pro), apoE-Tokyo/Maebashi (Lys143–Arg145 deletion), apoE-Guangzhou (Arg150Pro), and apoE-Kanto (Asp151dup) (PMID: 23407349; PMID: 39141311). Founder effects are documented for apoE-Sendai (eastern Japan) and apoE-Kyoto (China).

Environmental / modifier risk factors. Because penetrance is incomplete (many asymptomatic carriers exist in affected families), additional genetic, epigenetic, and/or environmental modifiers are inferred to contribute. Co-inheritance of additional apoE alleles (e.g., apoE2 Arg158Cys, apoE5 Glu3Lys) or other conditions has been proposed to modify expression in individual kindreds (PMID: 23407349; PMID: 29356944; PMID: 26955632).

"In addition to APOE mutation, other genetic and/or epigenetic factors are considered to be involved in the pathogenesis of LPG because of its low penetrance." — PMID: 23407349

Protective factors. No specific genetic or environmental protective factors are established. Early lipid-lowering therapy is associated with better renal outcomes (see Treatment), functioning as a modifiable disease-course factor rather than a prevention of onset.

Gene–environment interactions. Incomplete penetrance strongly implies gene-environment/gene-gene interaction, but specific interacting exposures are not well characterized.

3. Phenotypes

Phenotype frequencies are best quantified in an 11-patient Chinese cohort (mean age 33.82 years) (PMID: 38584145):

Phenotype Type Frequency Suggested HPO
Proteinuria Laboratory / clinical sign 10/11 (91%) HP:0000093 (Proteinuria)
Dyslipidemia (type III-like) Laboratory abnormality 10/11 (91%) HP:0003119 (Abnormal circulating lipid concentration); HP:0002155 (Hypertriglyceridemia)
Microscopic hematuria Laboratory / sign 6/11 (55%) HP:0000790 (Hematuria)
Positive family history — 5/11 (45%) —
Nephrotic syndrome Clinical syndrome 4/11 (36%) HP:0000100 (Nephrotic syndrome)
Edema Physical manifestation Common HP:0000969 (Edema)
Elevated serum apoE Laboratory abnormality Characteristic (not universal) HP:0003119 (related lipid abnormality)
Renal enlargement Imaging Reported HP:0000105 (Enlarged kidney)
Anemia Laboratory abnormality Reported HP:0001903 (Anemia)
Hypertension Clinical sign Associated with LDL-R–region variants HP:0000822 (Hypertension)
Chronic kidney disease / ESKD Outcome ~50% progress HP:0012622 (Chronic kidney disease); HP:0003774 (Stage 5 CKD)

"The mean age of the eleven patients was 33.82 years. Among them, five had a positive family history for LPG, ten presented with proteinuria, four exhibited nephrotic syndrome, and six presented with microscopic hematuria. Dyslipidemia was identified in ten patients." — PMID: 38584145

Age of onset. Predominantly adult-onset with an average age of presentation of 32 years (range 4–69) (PMID: 38438730). Pediatric and early-onset cases occur, including 6- and 7.5-year-old boys, a 12-year-old girl, and a 23-month-old boy with homozygous APOE Kyoto and parental consanguinity presenting as steroid-resistant nephrotic syndrome (PMID: 39993083; PMID: 22874113; PMID: 42417997).

"It is a monogenic disorder with autosomal dominant inheritance and the average age of presentation is 32 years (4-69 years)." — PMID: 38438730

Severity / progression / variability. Severity is variable and progression is generally chronic and progressive, often culminating in ESKD. A notable phenotypic nuance: a subset of patients are normolipidemic (e.g., certain APOE Kyoto and APOE Kanto cases with normal serum lipids and apoE), so normal lipids do not exclude LPG (PMID: 40186270; PMID: 42309892; PMID: 39141311).

"In contrast to previous cases, this patient lacked hyperlipidemia and ApoE was a Kyoto mutation." — PMID: 40186270

Quality of life impact. No formal EQ-5D/SF-36 data exist for LPG. Impact is inferred from nephrotic-range proteinuria, edema, and progression to dialysis-dependent ESKD, all of which substantially impair daily functioning. LPG can co-occur with IgA nephropathy, membranous nephropathy, or lupus nephritis, which can add to morbidity.

4. Genetic / Molecular Information

Causal gene. APOE (apolipoprotein E), HGNC:613, OMIM gene 107741; disease OMIM 611771; located at 19q13.32. LPG is caused by rare, protein-altering APOE variants — distinct from the common E2/E3/E4 isoform polymorphisms (though some patients carry combinations of a rare LPG variant with a common isoform allele).

Pathogenic variants. Causal variants cluster in/near the LDL-receptor-binding region (residues ~136–158). The table below lists the principal named variants (mature-protein numbering unless noted):

Variant name Change (mature protein) Type Notable feature
apoE-Sendai Arg145Pro Missense (Arg→Pro) Founder in eastern Japan; most frequent
apoE-Kyoto Arg25Cys (signal-inclusive Arg43Cys) Missense Founder in China; can be normolipidemic
apoE-Osaka/Kurashiki Arg158Pro Missense (Arg→Pro) Serum apoE can be normal
apoE-Chicago Arg147Pro Missense (Arg→Pro) —
apoE-Tokyo/Maebashi Lys143–Arg145 deletion In-frame deletion 9-nt deletion (c.480–488)
apoE-Guangzhou Arg150Pro Missense (Arg→Pro) Novel Chinese variant
apoE-Kanto Asp151dup In-frame duplication First duplication-type; progressed to ESKD

"LPG is primarily associated with heterozygous apoE mutations surrounding the low-density lipoprotein-receptor binding site, and it is histologically characterized by lamellated lipoprotein thrombi that lack foam cells." — PMID: 31874799

"More than 12 APOE mutations have been identified as causes of LPG, and APOE-Sendai (Arg145Pro) mutation was frequently detected in patients from the eastern part of Japan including Yamagata prefecture." — PMID: 23407349

Variant classification & type. Variants are pathogenic (ACMG/AMP), predominantly missense (frequently arginine→proline substitutions) plus small in-frame deletions/duplications. Origin is germline. Functional consequence is a conformational/structural defect (destabilization/aggregation) — effectively a toxic gain-of-function / dominant-negative-like behavior at the lipoprotein-particle level rather than simple loss of ligand function, consistent with autosomal-dominant inheritance.

Allele frequency. Causal variants are rare/absent in population databases; the apoE-Sendai founder variant was not detected in 2,023 controls, confirming rarity in the general population (PMID: 23407349).

Modifier genes / epigenetics. Incomplete penetrance implicates additional genetic/epigenetic modifiers; co-inheritance of apoE2 (Arg158Cys) or apoE5 (Glu3Lys) has been proposed to modify phenotype in specific families (PMID: 26955632; PMID: 29356944). No specific DNA-methylation/histone signatures have been defined for LPG.

Chromosomal abnormalities. None reported; LPG is a single-gene point-variant/small-indel disorder.

5. Environmental Information

LPG has no established environmental cause. There are no implicated toxins, radiation, pollutants, or occupational exposures; no lifestyle factor is established as causal; and no infectious agent triggers the disease. Incomplete penetrance implies that unidentified genetic/epigenetic/environmental modifiers influence whether carriers develop overt disease, but these remain uncharacterized (PMID: 23407349). Not applicable / not established for most environmental subcategories.

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation)

  1. A heterozygous APOE missense/in-frame variant near the LDL-receptor-binding region (e.g., Arg145Pro) results in an amino-acid change incompatible with normal helical packing of the N-terminal domain.
  2. This leads to thermodynamic destabilization of the apoE N-terminal four-helix bundle, loss of unfolding intermediates, and a shift toward a molten-globule-like state (demonstrated in vitro).
  3. The destabilized protein exposes hydrophobic surface to solvent, which results in increased aggregation propensity and protease sensitivity (demonstrated in vitro).
  4. Aggregation-prone mutant apoE leads to formation of aberrant, destabilized apoE-rich lipoprotein particles and impaired remnant-lipoprotein clearance, producing a type III–like dyslipidemia with elevated serum apoE (inferred from plasma profiles + in vitro particle data).
  5. These abnormal lipoproteins deposit within glomerular capillaries as lamellated lipoprotein thrombi (branch: a complementary mechanism posits impaired macrophage clearance of lipoproteins, explaining thrombi forming without foam cells).
  6. Thrombi occlude markedly dilated glomerular capillary loops, which results in proteinuria, hematuria, and reduced filtration.
  7. Chronic capillary occlusion and glomerular injury lead to progressive chronic kidney disease and, in ~50% of patients, ESKD (demonstrated by natural-history data).

"All three variants were found to have significantly reduced helical content, to expose a larger portion of hydrophobic surface to the solvent, and to be significantly thermodynamically destabilized, often lacking functionally relevant unfolding intermediates." — PMID: 23110818

"Overall, our data suggest that these mutations induce a generalized unfolding of the N-terminal domain of apoE3 toward a molten-globule-like structure." — PMID: 23110818

"LPG can be induced by thermodynamic destabilization, hydrophobic surface exposure, and the aggregation of apoE resulting from the incompatibility of apoE mutated residues within helical regions." — PMID: 31874799

Detail by category

7. Anatomical Structures Affected

"Immunofluorescence staining showed that the thrombi were strongly positive for apo A, B, and E. Granules and various sizes of vacuoles were observed in the thrombi under electron microscope." — PMID: 15498375

8. Temporal Development

"approximately half of the patients develop end-stage kidney disease within 1-27 years of disease onset" — PMID: 38769490

9. Inheritance and Population

"At present, 65 cases have been reported worldwide, although most patients are found in Japan and east Asian countries." — PMID: 16431249

"the haplotype of all APOE-Sendai mutations was identical, suggesting that APOE-Sendai mutation is common in Japanese patients probably through a founder effect." — PMID: 23407349

10. Diagnostics

Two-pillar diagnostic standard: (1) characteristic kidney biopsy and (2) molecular confirmation by APOE sequencing (PMID: 40306438).

Biopsy / histopathology. Light microscopy shows markedly dilated glomerular capillary loops filled with pale, weakly-staining lamellated lipoprotein thrombi. Staining profile: PAS weak-positive, Masson pale blue, silver/MT pale, Congo-red negative (excludes amyloid), Oil Red O / Sudan positive on frozen sections (confirms lipid), and apoE-positive by immunohistochemistry (also apoA, apoB positive). Immunofluorescence for immunoglobulins and complement is negative (distinguishes from immune-complex GN). Electron microscopy shows granular/vacuolated thrombi of variable electron density (PMID: 41405262; PMID: 15498375).

"These thrombi appeared PAS weak positive, MT pale blue, silver negative, and Congo-Red negative. These capillary luminal contents stained reddish with Oil-red O confirming lipid contents." — PMID: 41405262

Genetic testing. Single-gene APOE Sanger sequencing is the primary confirmatory test; whole-exome sequencing is increasingly used and can reveal co-inherited variants (e.g., COL4A5 in an Alport/LPG dual-diagnosis case) (PMID: 40306438; PMID: 41612256).

Supportive labs / biomarkers. Elevated serum apoE and apoB, hypertriglyceridemia, type III dysbetalipoproteinemia pattern (mid-band on electrophoresis). Caveat: serum apoE can be normal in some variants (Osaka, Kanto, normolipidemic Kyoto) — normal apoE does not exclude LPG (PMID: 21325775; PMID: 39141311).

Advanced / omics diagnostics. LC-MS/MS of laser-microdissected glomeruli demonstrates glomerular apoE enrichment, providing molecular confirmation of deposit composition (PMID: 38769490).

"Liquid chromatography-tandem mass spectrometry of laser-microdissected glomeruli from paraffin sections revealed an increase in ApoE." — PMID: 38769490

Differential diagnosis. Amyloidosis (Congo-red negative in LPG), thrombotic microangiopathy, cryoglobulinemic GN, fibronectin glomerulopathy, histiocytic glomerular lipidosis (e.g., macrophage activation syndrome), and apoE2-homozygote glomerulopathy (foam-cell rich) (PMID: 31874799; PMID: 37936128).

Screening. Cascade family screening (APOE sequencing ± urinalysis) is appropriate given autosomal-dominant inheritance; many carriers are asymptomatic (PMID: 41612256).

11. Outcome / Prognosis

"it may recur after kidney transplantation" — PMID: 40306438

"LPG patients with urine protein reduced more than 50% had a slower decrease in renal function than those with less urine protein reduction." — PMID: 32441489

12. Treatment

LPG is not steroid-responsive; immunosuppression is ineffective (PMID: 42417997). The mainstay is lipid-lowering therapy plus antiproteinuric RAAS blockade.

Therapy Example agents Evidence / effect Suggested NCIT
Fibrates (PPARα agonists) Fenofibrate, bezafibrate Most-reported therapy; reduce proteinuria, can induce complete remission NCIT:C29475 (Fenofibrate); fibric acid class
Selective PPARα modulator Pemafibrate Complete remission (0.05 g/gCr) within 7 months in a reported case PPAR-alpha agonist class
RAAS blockade (adjunct) Telmisartan, losartan, ACEi/ARB Antiproteinuric; used with fibrates NCIT:C66951 (Losartan); ARB class
Statins Various Benefit in selected patients (statin monotherapy sustained renal stability up to 3 years) NCIT:C1518 (HMG-CoA reductase inhibitor)
Supportive Lipid/BP control, diet Standard CKD/nephrotic supportive care —

"Complete remission (0.05 g/gCr) was achieved within 7 months, and she remained stable thereafter." — PMID: 42371225

Representative responses: a boy with apoE-Tokyo/Maebashi had urine protein turn negative within 1 week on fenofibrate + telmisartan (PMID: 39993083); complete resolution with fenofibrate was reported from Pakistan (PMID: 38327135); and sustained benefit with statin monotherapy over 3 years in a young Chinese man with apoE-Kyoto (PMID: 30685233). In normolipidemic LPG, lipid-lowering may be withheld and ARB used alone (PMID: 42309892).

Advanced/experimental therapeutics. No approved gene, cell, or RNA-based therapy exists. Because the disease is driven by a circulating misfolded protein, therapies targeting apoE production or conformation are conceptually attractive but remain experimental. Early initiation of fibrate therapy is emphasized to prevent renal dysfunction (PMID: 24149835).

"the administration of fibrate with the intensive control of triglyceride and apolipoprotein E particularly from the early phase will ameliorate LPG and prevent renal dysfunction." — PMID: 24149835

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Primary model: apoE-deficient (Apoe⁻/⁻) mouse reconstituted with mutant human apoE via adenoviral transduction. This is the key in vivo system validating LPG etiology.

Model Method Result Reference
apoE-Sendai (Arg145Pro) in Apoe⁻/⁻ Adenoviral transduction LPG-like lesions in 40/50 mice (24 mild, 13 moderate, 3 severe); dilated lumens with Oil Red O/Sudan-positive lipid thrombi PMID: 19459027
apoE-Kyoto (p.R43C) in Apoe⁻/⁻ Adenoviral transduction Reproduced LPG pathology; enabled comparison with apoE-Sendai PMID: 33663537
apoE-Sendai general validation Adenoviral transduction in Apoe⁻/⁻ Confirmed etiologic role of mutant apoE in LPG PMID: 16431249

"The virus-mediated transduction of apoE Sendai resulting in the development of LPG in apoE-deficient mice confirms the etiologic role of apoE mutation in LPG." — PMID: 16431249

"Characteristic lesions were dilated vascular lumens mimicking lipoprotein thrombi in human LPG. Similar changes were found in hematoxylin-eosin stained sections of aged apoE KO mice." — PMID: 19459027

Phenotype recapitulation. Models reproduce the hallmark glomerular lipoprotein thrombi and confirm the pathogenic role of mutant apoE. Important control: aged Apoe⁻/⁻ mice develop superficially similar dilated-lumen lesions, but these contain proteins/fibrils rather than lipid, distinguishing spontaneous knockout lesions from true mutant-apoE-driven LPG (PMID: 19459027).

Model limitations. Adenoviral expression is transient and non-germline; models do not fully recapitulate chronic progression to ESKD. No germline knock-in mouse for human LPG variants is established in the reviewed literature.

In vitro models. Recombinant apoE3-based mutants (R145P/Sendai, R147P/Chicago, R158P/Osaka, and non-proline R25C/Kyoto) characterized biophysically establish the destabilization/aggregation mechanism (PMID: 23110818; PMID: 30309894).

Mechanistic Model / Interpretation

  APOE missense/in-frame variant (near LDL-R binding region, res ~136–158)
                         │  (e.g., Arg145Pro = apoE-Sendai)
                         ▼
  Thermodynamic destabilization of apoE N-terminal 4-helix bundle
   (↓ α-helix, loss of unfolding intermediates → molten-globule-like)   [in vitro]
                         │
                         ▼
  Hydrophobic surface exposure → aggregation + protease sensitivity      [in vitro]
                         │
          ┌──────────────┴───────────────┐
          ▼                              ▼
  Aberrant apoE-rich lipoprotein     Impaired macrophage clearance
  particles; ↓ remnant clearance     of lipoproteins (complementary;
  → type III–like dyslipidemia,      explains thrombi WITHOUT foam cells)
  ↑ serum apoE (variant-dependent)
          │                              │
          └──────────────┬───────────────┘
                         ▼
  Lamellated lipoprotein thrombi deposit in dilated glomerular capillaries
   (apoE/apoA/apoB +, Oil Red O +, Congo-red −, Ig/complement −)
                         ▼
  Capillary occlusion → proteinuria, microscopic hematuria, ↓ GFR
                         ▼
  Progressive CKD → ESKD in ~50% (1–27 yr); recurs post-transplant
                         │
                         ▼   (therapeutic node)
  Fibrates / pemafibrate + RAAS blockade → ↓ proteinuria → slower eGFR decline

Upstream vs downstream. The APOE variant and apoE misfolding/aggregation are upstream; lipoprotein-thrombus deposition and glomerular capillary occlusion are intermediate; proteinuria, CKD, and ESKD are downstream. The disease unifies a spectrum of apoE-related glomerular disorders: LPG (heterozygous LDL-R–region variants, lamellated thrombi, no foam cells) is distinct from apoE2-homozygote glomerulopathy (glomerulosclerosis with foam-cell infiltration) and apoE-Toyonaka (Ser197Cys)+apoE2/2 (membranous-like), yet all converge on apoE conformational abnormality and renal lipid accumulation (PMID: 31874799).

"ApoE2 homozygote glomerulopathy has been found in individuals expressing homozygous apoE2/2. This was characterized histologically by glomerulosclerosis with marked infiltration of foam cells derived from macrophages" — PMID: 31874799

Evidence Base

PMID Contribution Evidence type
40306438 Defines LPG as ultra-rare APOE disorder; two-pillar diagnosis; post-transplant recurrence Human clinical (review/cases)
35602473 >200 cases over 30 years; meta-analysis Human, meta-analysis
23110818 Thermodynamic destabilization / molten-globule mechanism of apoE mutants In vitro / biophysical
30309894 Destabilization/aggregation for non-proline mutants (R25C/Kyoto) In vitro
24149834 Structural basis review of LPG mutations Computational/structural review
31874799 Unifying conformational mechanism; distinguishes apoE-related glomerular disorders Review
16431249 In vivo confirmation (apoE-Sendai in Apoe⁻/⁻); 65-case epidemiology Mouse model / review
19459027 apoE-Sendai mouse model; distinguishes aged KO lesions Mouse model
33663537 apoE-Kyoto mouse model Mouse model
23407349 Founder haplotype of apoE-Sendai; incomplete penetrance Human genetics
38584145 Phenotype frequencies in 11-patient cohort Human clinical
38438730 Age of onset (32 yr; 4–69); AD inheritance; pediatric case Human clinical
32441489 Proteinuria reduction → slower eGFR decline; genotype-BP/apoE correlation Human clinical
38769490 ESKD in ~50% (1–27 yr); LC-MS/MS glomerular apoE; fibrate+losartan Human clinical
42371225 Complete remission with pemafibrate Human clinical
41405262 Histochemical staining profile for diagnosis Human clinical
15498375 apoE/apoA/apoB-positive vacuolated thrombi Human clinical
40186270 / 42309892 Normolipidemic LPG (APOE Kyoto) Human clinical
42417997 Homozygous APOE Kyoto, infantile, steroid-resistant Human clinical
26955632 Macrophage infiltration; LPG vs apoE2-GN bridge Human clinical
27277824 apoE normal function (LDL-R ligand) Review
10359567 apoE structure → VLDL clearance (conservation) Mouse model
41612256 Incomplete penetrance; WES + biopsy; cascade screening Human clinical

Limitations and Knowledge Gaps

  1. No formal epidemiology. Prevalence and incidence are not quantified; estimates rest on cumulative case counts (>200 worldwide). No Orphanet prevalence class exists.
  2. Ascertainment bias. The heavy East-Asian representation partly reflects founder variants and may be amplified by awareness/reporting bias; true global distribution is uncertain.
  3. Mechanistic branch not fully resolved. The relative contributions of apoE misfolding/aggregation versus impaired macrophage lipoprotein clearance to thrombus formation remain to be dissected in vivo.
  4. Model limitations. Available mouse models use transient adenoviral (non-germline) expression and do not fully recapitulate chronic ESKD progression; no validated germline knock-in model is reported.
  5. Penetrance modifiers unknown. The genetic/epigenetic/environmental factors explaining incomplete penetrance and normolipidemic phenotypes are not identified.
  6. Treatment evidence is low-level. Efficacy data come from case reports and small series, not randomized trials; optimal agent (fibrate vs statin vs pemafibrate), timing, and genotype-specific response are not established.
  7. No QoL/mortality data. Disease-specific quality-of-life and mortality metrics are absent.

Proposed Follow-up Experiments / Actions

  1. Germline knock-in mouse models of recurrent human variants (apoE-Sendai Arg145Pro, apoE-Kyoto) to study chronic progression to ESKD and test therapeutics longitudinally.
  2. Prospective international LPG registry with standardized genotype, histology, serum apoE, and renal-outcome capture to establish prevalence, natural history, and genotype–phenotype correlations (including normolipidemic variants).
  3. Randomized or well-controlled comparative studies of fibrates (incl. pemafibrate) vs statins vs combination with RAAS blockade, with proteinuria and eGFR-slope endpoints, stratified by variant and baseline lipids.
  4. Mechanistic dissection of the macrophage-clearance branch (e.g., macrophage-specific manipulation in reconstituted Apoe⁻/⁻ mice) to clarify why thrombi form without foam cells.
  5. apoE-targeted therapeutic exploration — small molecules/chaperones that stabilize the apoE N-terminal domain, or RNA-based approaches lowering mutant apoE — given that circulating pathogenic apoE drives disease and post-transplant recurrence.
  6. Routine cascade APOE screening protocols for relatives of probands, paired with early lipid-lowering intervention trials in asymptomatic carriers to test secondary prevention.
  7. Structural/biophysical profiling of newer variants (e.g., apoE-Kanto Asp151dup) to confirm the generality of the destabilization-aggregation model across variant classes (missense, deletion, duplication).

Report compiled from 43 reviewed papers and 9 confirmed findings across 5 investigation iterations. Evidence sources are distinguished as human clinical, mouse model, in vitro/biophysical, or review/computational throughout.